Found: 18
Select item for more details and to access through your institution.
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 755, doi. 10.1002/ajh.27203
- By:
- Publication type:
- Article
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. E470, doi. 10.1002/ajh.26732
- By:
- Publication type:
- Article
MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S360, doi. 10.1016/S2152-2650(21)01829-2
- By:
- Publication type:
- Article
Poster: MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01455-5
- By:
- Publication type:
- Article
Long-term follow-up of recovered MPN patients with COVID-19.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 3, p. 371, doi. 10.1111/ejh.13561
- By:
- Publication type:
- Article
Increased survival due to lower toxicity for high‐risk T‐cell acute lymphoblastic leukemia patients in two consecutive pediatric‐inspired PETHEMA trials.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 1, p. 79, doi. 10.1111/ejh.13178
- By:
- Publication type:
- Article
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 4, p. 407, doi. 10.1111/ejh.12846
- By:
- Publication type:
- Article
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 13, p. 2441, doi. 10.1002/cncr.34195
- By:
- Publication type:
- Article
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. e58, doi. 10.1111/bjh.18655
- By:
- Publication type:
- Article
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 4, p. 529, doi. 10.1111/bjh.18440
- By:
- Publication type:
- Article
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 2, p. 447, doi. 10.1007/s00277-022-05044-x
- By:
- Publication type:
- Article
Prognostic risk models for transplant decision-making in myelofibrosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
- Published in:
- EJHaem, 2024, v. 5, n. 1, p. 105, doi. 10.1002/jha2.854
- By:
- Publication type:
- Article
Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 388
- By:
- Publication type:
- Article
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 377
- By:
- Publication type:
- Article
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof‐of‐concept study.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 7, p. 1, doi. 10.1002/jmv.28933
- By:
- Publication type:
- Article